These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11206703)

  • 1. Angiotensin II type 1 receptor antagonist versus angiotensin I-converting enzyme inhibitor in experimental renal diseases.
    Jover B; Demeilliers B
    Fundam Clin Pharmacol; 2000; 14(6):541-8. PubMed ID: 11206703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
    Weber MA
    J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists.
    Campbell DJ
    Clin Exp Pharmacol Physiol Suppl; 1996; 3():S125-31. PubMed ID: 8993851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ACE inhibition and angiotensin AT1 receptor blockade on renal and blood pressure response to L-arginine in humans.
    Komers R; Komersova K; Kazdova L; Ruzickova J; Pelikanova T
    J Hypertens; 2000 Jan; 18(1):51-9. PubMed ID: 10678543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotective mechanisms of angiotensin II antagonism in experimental chronic renal failure.
    Uhlenius N; Miettinen A; Vuolteenaho O; Tikkanen I
    Kidney Blood Press Res; 2002; 25(2):71-9. PubMed ID: 12077487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension.
    Weber MA
    Am J Hypertens; 1999 Dec; 12(12 Pt 3):189S-194S. PubMed ID: 10619571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pathophysiological mechanisms of the renin-angiotensin system and its pharmacologic modification by ACE inhibitors or angiotensin II (type 1) receptor blockers in cardiovascular diseases].
    Huber K; Pachinger O; Pichler M; Klein W
    Z Kardiol; 1997 Apr; 86(4):239-50. PubMed ID: 9235795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of the renin-angiotensin and endothelin systems on progressive renal injury.
    Cao Z; Cooper ME; Wu LL; Cox AJ; Jandeleit-Dahm K; Kelly DJ; Gilbert RE
    Hypertension; 2000 Oct; 36(4):561-8. PubMed ID: 11040236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of renal glomerular angiotensin II receptors by ace inhibition and AT1 receptor antagonism.
    Haddad G; Amiri F; Garcia R
    Regul Pept; 1997 Jan; 68(2):111-7. PubMed ID: 9110382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin-angiotensin blockade improves renal cGMP production via non-AT(2)-receptor mediated mechanisms in hypertension-induced by chronic NOS inhibition in rat.
    Uhlenius N; Vuolteenaho O; Tikkanen I
    J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):233-9. PubMed ID: 11881129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
    Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
    Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin receptor blockers and the kidney: possible advantages over ACE inhibition?
    Cooper ME; Webb RL; de Gasparo M
    Cardiovasc Drug Rev; 2001; 19(1):75-86. PubMed ID: 11314602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers.
    Weir MR; Henrich WL
    Curr Opin Nephrol Hypertens; 2000 Jul; 9(4):403-11. PubMed ID: 10926177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valsartan and the kidney: present and future.
    Mann JF
    J Cardiovasc Pharmacol; 1999; 33 Suppl 1():S37-40; discussion S41-3. PubMed ID: 10028953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
    Hulthén UL; Cao Z; Rumble JR; Cooper ME; Johnston CI
    Am J Hypertens; 1996 Sep; 9(9):895-901. PubMed ID: 8879346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.
    Wada T; Inada Y; Ojima M; Sanada T; Shibouta Y; Nishikawa K
    Hypertens Res; 1996 Jun; 19(2):75-81. PubMed ID: 10968199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of quinapril on expression of eNOS, ACE, and AT1 receptor in deoxycorticosterone acetate-salt hypertensive rats.
    Hara K; Kobayashi N; Watanabe S; Tsubokou Y; Matsuoka H
    Am J Hypertens; 2001 Apr; 14(4 Pt 1):321-30. PubMed ID: 11336177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
    Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
    Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.